Abbvie Successful Phase 3 Study for Upadacitinib in Patients with Crohn's Disease
24.02.2022 - (PLX AI) – Abbvie Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ) Improved Clinical and Endoscopic Outcomes in Patients with Crohns Disease.In U-EXCEL, the second of two Phase 3 induction studies, a significantly higher proportion of ...
Abbvie Successful Phase Abbvie Second Phase Study Confirms Upadacitinib Improved Clinical Endoscopic Outcomes
Source: wallstreet-online.de